CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1

European Journal of Medical Research

Volumn 12, Issue 9, 2007, Pages 427-434

  Bredeek, U Fritz ^a   Harbour, Michael J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; APLAVIROC; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; CELSENTRI; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOATES; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CCR5; SPIRO COMPOUNDS; TRIAZOLES;

EID: 35549007987     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Currier J, Lazzarin A, Kleim J-P, Steel H, Millard J, Bonny T, et al. 2006. Safety and antiviral activity of the novel CCR5 Antagonist Aplaviroc in combination with Zidovudin + Lamivudine in HIV-Infected Therapy-naïve Subjects, 8th International Congress on Drug Therapy in HIV; November 12-16, 2006; Glasgow, United Kingdom. Abstract P392.
2. Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naive HTV-infected patients. Lancet 2006;367: 711-713.
3. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
4. Greaves W, Landovitz R, Fatkenheuer G, et al. Late virologic breakthrough in treatment-naïve patients on a regimen of Combivir + vicriviroc. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado. Abstract 161LB.
5. Gulick R et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV + treatment-experienced subjects: 48-week results. Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract TUAB102
6. Gulick RM, Su Z, Flexner C et al. and others (for the AIDS Clinical Trials Group 5211 Team). Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. Journal of Infectious Diseases 196(2): 304-312. July 15, 2007.
7. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194:926-930.
8. Kitrinos, KM, Irlbeck, DM, LaBranche, CC, Madsen, HA, and Demarest, JF. 2006. Virologic characterization of treatment naive subjects failing an aplaviroc-based regimen with either lamivudine/zidovudine or lopinavir/ ritonavir. XV International Drug Resistance Workshop; June 13-17, 2006; Sitges, Spain. Abstract 21
9. Lalezari J, Thomson M, Kumar P et al. Antiviral activity and safety of 873140, a novel CCR5 Antagonist, during short term monotherapy in HIV-infected adults. AIDS 2005; 19:1443-8
10. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experiences subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. XVI International AIDS Conference. August 13-18, 2006. Toronto. Abstract THLB0215
11. Moyle G, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG: Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV-1 Infection, The Journal of Infectious Diseases, volume 191 (2005), pages 866-872
12. Nichols WG, Steel HM, Bonny TM, Min SS, Curtis L, Kabeya K, Clumeck N. Hepatotoxicity observed in clinical trials of aplaviroc (APL, 873140). Special Oral Communication, 2005 EACS, Dublin, Ireland.
13. Pfizer, Selzenrty, Full Prescribing Information, August 2007. http://media.pfizer.com/files/products/uspi_maraviroc.pdf
14. Ryan CT. Trials of aplaviroc halted in treatment-naive patients. AIDS Clin Care. November 2005;17(11):107-108
15. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maravsroc vs efavirenz, both in combination with Combivir for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. 4th International AIDS Society conference; July 22-25, 2007; Sydney, Australia. WESS104
16. Schurmann D; Fatkenheuer G; Reynes J; Michelet C, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS. 21(10):1293-1299, June 2007.
17. Shepherd J, Jacobson L, Qiao W, et al. Analysis of the timing of CXCR4-tropic HIV emergence in the MACS cohort. XVI International AIDS Conference. August 13-18, 2006. Toronto. Abstract TUPE0001.
18. Yeni P, Rockstroh J, LaMarca A, Madison S, Nichols G, et al. Safety and Antiviral activity of the novel CCR5 Anttagonist Aplaviroc in Combination with Lopinavir/itonavir in HIV Infected Thearpy naïve subjects. 8th International Congress on Drug Therapy in HIV; November 12-16, 2006; Glasgow United Kingdom. Abstract P394.